Fleur Herrenschmidt

Novartis (Basel)
Head Legal Region Europe

Fleur Herrenschmidt is the head of legal affairs at Novartis. She was an associate in Allen & Overy and a specialist in competition matters. She joined the competition practice in January 2006. She has experience in the fields of antitrust law, distribution, and restrictive practices. She also assists clients in the framework of competition investigations. She has a particular expertise in the regulated sectors, and especially in the pharmaceutical and telecommunications sectors. LLM, London School of Economics (1995), Post Master’s degree in European Legal Studies (DESS), Paris X (1996), Master degree in European Law, College of Europe, Bruges (1997), Avocat à la Cour (2001)

Linked authors

Novartis (New Jersey)
Novartis (Basel)
Novartis (Rueil-Malmaison)

Articles

29515 Bulletin

Fleur Herrenschmidt, Olivier Fréget The French Competition Authority issues a landmark interim decision on competition between princeps and generics (Arrow / Schering-Plough)

6753

By a decision of 11 December 2007, the Competition Council issued yet another decision concerning the (difficult) competition between princeps and generics at the time when the latter enter a market which becomes accessible upon expiry of the former’s intellectual property rights. Although this (...)

Fleur Herrenschmidt, Olivier Fréget The French Supreme Administrative Court annuls a State’s decision discriminating the reimbursement’s rate between princeps and generic drugs (GlaxoSmithKline)

4260

1. The Regulatory Context: positive discrimination as a starting point and the TFR a possible end to it Sales of reimbursable medicines to consumers are heavily regulated in France, from the level of the pharmaceutical company manufacturing them all the way through to the ultimate individual (...)

6640 Review

Fleur Herrenschmidt, Olivier Fréget Lobbying and Competition Law

6640

Both the efficiency and the legitimacy of sector-specific regulation rely on the guarantee that the relevant regulators have not been «captured» by those they are expected to regulate. The present article proceeds with a brief analysis, first, of the formal mechanisms that reduce the risks of (...)

Send a message